OncoTherapy Science, Inc.
4564.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥750 | ¥610 | ¥1,135 | ¥1,154 |
| % Growth | 22.9% | -46.2% | -1.6% | – |
| Cost of Goods Sold | ¥763 | ¥788 | ¥1,093 | ¥1,040 |
| Gross Profit | -¥13 | -¥178 | ¥42 | ¥114 |
| % Margin | -1.7% | -29.1% | 3.7% | 9.9% |
| R&D Expenses | ¥491 | ¥678 | ¥716 | ¥1,730 |
| G&A Expenses | ¥294 | ¥265 | ¥432 | ¥436 |
| SG&A Expenses | ¥294 | ¥265 | ¥432 | ¥436 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥785 | ¥943 | ¥1,148 | ¥2,167 |
| Operating Income | -¥798 | -¥1,121 | -¥1,106 | -¥2,053 |
| % Margin | -106.4% | -183.7% | -97.5% | -177.9% |
| Other Income/Exp. Net | -¥15 | -¥165 | -¥10 | -¥518 |
| Pre-Tax Income | -¥813 | -¥1,286 | -¥1,116 | -¥2,570 |
| Tax Expense | ¥2 | ¥2 | ¥2 | ¥1 |
| Net Income | -¥815 | -¥1,288 | -¥1,119 | -¥2,572 |
| % Margin | -108.7% | -211.1% | -98.6% | -222.9% |
| EPS | -3.12 | -6.05 | -5.81 | -13.72 |
| % Growth | 48.4% | -4.1% | 57.7% | – |
| EPS Diluted | -3.12 | -6.05 | -5.81 | -13.72 |
| Weighted Avg Shares Out | 261 | 213 | 193 | 187 |
| Weighted Avg Shares Out Dil | 261 | 213 | 193 | 187 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥1 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥1 | ¥0 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥797 | ¥0 | ¥16 | ¥17 |
| EBITDA | -¥812 | -¥1,285 | -¥1,091 | -¥2,037 |
| % Margin | -108.2% | -210.7% | -96.1% | -176.6% |